NCT00687622 - Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | Biotech Hunter

Enrollment

206

Participants

Timeline

Start Date

July 28, 2008

Primary Completion Date

June 7, 2011

Study Completion Date

November 8, 2011

Conditions

Solid Tumours

Interventions

DRUG

GSK1120212

Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses

Trial Locations (12)

GSK Investigational Site, Albany

GSK Investigational Site, Philadelphia

GSK Investigational Site, Norfolk

GSK Investigational Site, Fort Myers

GSK Investigational Site, Ocoee

GSK Investigational Site, Nashville

GSK Investigational Site, Kettering

GSK Investigational Site, Dallas

GSK Investigational Site, Houston

GSK Investigational Site, Aurora

GSK Investigational Site, Scottsdale

GSK Investigational Site, Las Vegas